Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN)
Graphical abstract
Section snippets
Acknowledgments
We thank Hien Diep for in vitro ADME support, Scot Mente for statistical analysis and helpful discussions, and Mark Tebbe and James Loch for contributions to compound design and synthesis. We also thank Viva Biotech (Shanghai) Ltd. for the FASN co-crystal structure with compound 22.
References (15)
- et al.
Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression
EBioMedicine
(2015) - et al.
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy
Bioorg Med Chem Lett
(2018) - et al.
Medicinal chemistry approaches to avoid aldehyde oxidase metabolism
Bioorg Med Chem Lett
(2012) - et al.
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Nat Rev Cancer
(2007) - et al.
Fatty acid synthase inhibitors: new directions for oncology
Expert Opin Investig Drugs
(2007) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity
Cancer Res
(2004)- et al.
Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction
FEBS J
(2008)
There are more references available in the full text version of this article.
Cited by (0)
- 1
Current Address: KSQ Therapeutics, 610 Main Street, Cambridge, MA 02139, USA.
- 2
Current Address: Foghorn Therapeutics, 100 Binney Street, Suite 610, Cambridge, MA 02142, USA.
© 2019 Elsevier Ltd. All rights reserved.